The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?

Christian Lubich, Peter Allacher, Maurus de la Rosa, Alexander Bauer, Thomas Prenninger, Frank Michael Horling, Jürgen Siekmann, Johannes Oldenburg, Friedrich Scheiflinger, Birgit Maria Reipert

Publikation: Beitrag in FachzeitschriftArtikelBegutachtung


Purpose: Recent findings demonstrated anti-PEG antibody formation in some healthy individuals and patients who have not received PEGylated biotherapeutics. Some of these findings evoked criticism because of shortcomings in the antibody assays used. To better understand this topic, we established robust antibody analytics and screened two cohorts of healthy individuals and one cohort of hemophilia patients for the expression of anti-PEG antibodies. Methods: A flow cytometry approach and a fully validated ELISA platform were established to detect specific anti-PEG antibodies. Immunohistochemistry was used to test for potential binding of anti-PEG antibodies to human tissues. Results: IgM and/or IgG anti-PEG antibodies are expressed by some healthy individuals and by some patients with hemophilia who have not received PEGylated biotherapeutics. These antibodies can be either transient or persistent and recognize PEGs of different sizes with or without terminal methoxy groups. Age and location of healthy individuals influence the prevalence of IgG but not of IgM antibodies. Anti-PEG antibodies do not cross-react with human tissues supporting the safety of the antibodies. Conclusion: We confirm that some healthy individuals and some patients with hemophilia express specific antibodies against PEG which are not associated with any pathology and do not bind to human tissues.

Seiten (von - bis)2239-2249
FachzeitschriftPharmaceutical Research
PublikationsstatusVeröffentlicht - 1 Sep. 2016


Untersuchen Sie die Forschungsthemen von „The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?“. Zusammen bilden sie einen einzigartigen Fingerprint.

Dieses zitieren